NCT03625882Completed
Survey Study for Velaglucerase Alfa (VPRIV) in Japan
VPRIV Drug Use-Result Survey (Japan)
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 63 (actual)
- First submitted
- 8 Aug 2018
- Start date
- 2 Sept 2014
- Primary completion date
- 14 May 2024
- Lead sponsor
- Takeda
- Diseases
- Gaucher disease
- NCT number
- NCT03625882
What you commit to
- Study type: Observational
- Participants enrolled: 63
- From 2 Sept 2014 to the primary completion date, 14 May 2024
- 31 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Male or female participants with a confirmed diagnosis of Gaucher disease
- Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease
- Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period
Sex: All · Does not accept healthy volunteers
Sites (31)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.